Structure via PubChem · Public domain (PubChem)
moclobemide
Sign in to saveAlso known as GNF-Pf-695, Manerix®, Moclobemid, Moclamine, 4-Chloro-N-(2-(4-morpholinyl)ethyl)benzamide, 4-Chloro-N-(2-morpholin-4-yl-ethyl)-benzamide, 4-Chlor-N-(2-morpholinoethyl)benzamid
Moclobemide, sold under the brand names Amira, Aurorix, Clobemix, Depnil and Manerix among others, is a reversible inhibitor of monoamine oxidase A (RIMA) drug primarily used to treat depression and social anxiety. It is not approved for use in the United States, but is approved in other Western countries such as Canada, the United Kingdom and Australia. It is produced by affiliates of the Hoffmann–La Roche pharmaceutical company. Initially, Aurorix was also marketed by Roche in South Africa, but was withdrawn after its patent rights expired and Cipla Medpro's Depnil and Pharma Dynamic's Clori
Key facts
- Drug.UNII
- PJ0Y7AZB63
- Drug.Verifiedfields
- changed
- Drug.verifiedrevid
- 457784738
- Drug.image
- Moclobemide.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 250px
- Drug.tradename
- Amira, Aurorix, Clobemix, Depnil, Manerix, others
- Drug.pregnancy_AU
- B3
- Drug.routes_of_administration
- Oral
- Drug.ATC_prefix
- N06
- Drug.ATC_suffix
- AG02
- Drug.legal_AU
- S4
- Drug.legal_BR
- C1
- Drug.legal_CA
- Rx-only
- Drug.legal_UK
- POM
- Drug.bioavailability
- 55–95% (increases with repeat administration)
- Drug.protein_bound
- 50%
- Drug.metabolism
- Liver
via Wikipedia infobox
Chemical data
- Formula
- C13H17ClN2O2
- Molecular weight
- 268.74 g/mol
- IUPAC name
- 4-chloro-N-(2-morpholin-4-ylethyl)benzamide
- SMILES
- C1COCCN1CCNC(=O)C2=CC=C(C=C2)Cl
- InChIKey
- YHXISWVBGDMDLQ-UHFFFAOYSA-N
- XLogP
- 1.5
- Polar surface area
- 41.6 Ų
- H-bond donors
- 1
- H-bond acceptors
- 3
- Formal charge
- 0
via PubChem
Research
1,095 papers- Moclobemide.Lancet (London, England) · 1993
- Moclobemide: therapeutic use and clinical studies.CNS drug reviews · 2003
- Moclobemide: evolution, pharmacodynamic, and pharmacokinetic properties.CNS drug reviews · 2002
- Moclobemide--placebo-controlled trials.International clinical psychopharmacology · 1993
- Moclobemide. An update of its pharmacological properties and therapeutic use.Drugs · 1996
via PubMed
~29 min read
Encyclopedic overview
24 sectionsContents
- Medical uses
- Psychiatric disorders
- Combination with psychedelics
- Special populations
- Pregnancy and lactation
- Children
- Elderly
- Contraindications
- Adverse effects
- Tolerance and withdrawal
- Overdose
- Preclinical toxicology
- Interactions
- Dietary interactions
- Pharmacology
- Pharmacodynamics
- Pharmacokinetics
- History
- Society and culture
- Brand names
- See also
- References
- Further reading
- External links
Moclobemide, sold under the brand names Amira, Aurorix, Clobemix, Depnil and Manerix among others, is a reversible inhibitor of monoamine oxidase A (RIMA) drug primarily used to treat depression and social anxiety. It is not approved for use in the United States, but is approved in other Western countries such as Canada, the United Kingdom and Australia. It is produced by affiliates of the Hoffmann–La Roche pharmaceutical company. Initially, Aurorix was also marketed by Roche in South Africa, but was withdrawn after its patent rights expired and Cipla Medpro's Depnil and Pharma Dynamic's Clorix became available at half the cost.
No significant rise in blood pressure occurs when moclobemide is combined with amines such as tyramine-containing foods or pressor amine drugs, unlike with the older irreversible and non-selective monoamine oxidase inhibitors (MAOIs), which cause a severe rise in blood pressure with such combination. Due to the lack of anticholinergic, cardiovascular, cognitive and psychomotor impairments moclobemide is advantageous in the elderly as well as those with cardiovascular disease.
Excerpted from Wikipedia’s “moclobemide” article, available under the CC BY-SA 4.0 licence.